Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. An updated coronary risk profile: a statement for health professionals. Anderson KM, Wilson PW, Odell PM, Kannel WB. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. Optimizing statin treatment for primary prevention of coronary artery disease. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Individualized guidelines: the potential for increasing quality and reducing costs. Eddy DM, Adler J, Patterson B, Lucas D, Smith KA, Morris M. Medicine in the era of outcomes measurement. Cardiovascular risk reduction guidelines in adults: cholesterol guideline update (ATP IV) hypertension guideline update (JNC 8) obesity guideline update (Obesity 2) integrated cardiovascular risk reduction guideline. National Heart, Lung, and Blood Institute.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |